ECSP055679A - Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf) - Google Patents

Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)

Info

Publication number
ECSP055679A
ECSP055679A EC2005005679A ECSP055679A ECSP055679A EC SP055679 A ECSP055679 A EC SP055679A EC 2005005679 A EC2005005679 A EC 2005005679A EC SP055679 A ECSP055679 A EC SP055679A EC SP055679 A ECSP055679 A EC SP055679A
Authority
EC
Ecuador
Prior art keywords
tgf
derivatives
growth factor
transforming growth
inhibitors
Prior art date
Application number
EC2005005679A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP055679A publication Critical patent/ECSP055679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen nuevos compuestos de pirazol, incluyendo sus derivados, intermedios para su preparación, composiciones farmacéuticas que los contienen y su uso medicinal. Los compuestos de la presente invención son inhibidores potentes de la ruta de señalización del factor de crecimiento transformante (TGF)-B. Son de utilidad en el tratamiento de diversos estados de enfermedad relacionados con TGF incluyendo, por ejemplo cáncer y enfermedades fibróticas.
EC2005005679A 2002-09-18 2005-03-16 Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf) ECSP055679A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02

Publications (1)

Publication Number Publication Date
ECSP055679A true ECSP055679A (es) 2005-05-30

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005679A ECSP055679A (es) 2002-09-18 2005-03-16 Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)

Country Status (27)

Country Link
US (4) US6958354B2 (es)
EP (2) EP2165708A3 (es)
JP (1) JP4519657B2 (es)
KR (1) KR20050044807A (es)
CN (1) CN1681501A (es)
AP (1) AP2005003263A0 (es)
AR (1) AR041272A1 (es)
AT (1) ATE450258T1 (es)
AU (1) AU2003259475A1 (es)
BR (1) BR0314302A (es)
CA (1) CA2496295C (es)
CO (1) CO5550456A2 (es)
DE (1) DE60330362D1 (es)
EA (1) EA200500377A1 (es)
EC (1) ECSP055679A (es)
ES (1) ES2335099T3 (es)
HR (1) HRP20050247A2 (es)
IS (1) IS7698A (es)
MA (1) MA27440A1 (es)
MX (1) MXPA05002376A (es)
NO (1) NO20050838L (es)
OA (1) OA12929A (es)
PA (1) PA8583201A1 (es)
PE (1) PE20040988A1 (es)
PL (1) PL375979A1 (es)
UY (1) UY27985A1 (es)
WO (1) WO2004026306A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
AU2003256003A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
CA2496295C (en) * 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
AU2005280167A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
AU2005295734A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
WO2009016460A2 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
DK3470409T3 (da) * 2016-06-13 2020-05-11 Genfleet Therapeutics Shanghai Inc Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer
US11266647B2 (en) * 2016-10-26 2022-03-08 Icahn School Of Medicine At Mount Sinai Method for increasing cell proliferation in pancreatic beta cells, treatment method, and composition
AU2017357333A1 (en) * 2016-11-14 2019-05-02 Jiangsu Hengrui Medicine Co., Ltd. 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019114792A1 (zh) * 2017-12-13 2019-06-20 劲方医药科技(上海)有限公司 一种TGF-βRI抑制剂的晶型、盐型及其制备方法
WO2019136320A1 (en) 2018-01-05 2019-07-11 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
WO2020003219A1 (en) * 2018-06-29 2020-01-02 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives as insecticides and fungicides
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021011224A2 (pt) 2018-12-11 2021-08-24 Theravance Biopharma R&D Ip, Llc Inibidores de alk5
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
WO2021105317A1 (en) 2019-11-28 2021-06-03 Origo Biopharma, S.L. Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
IL132736A0 (en) 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002225730A1 (en) 2000-11-16 2002-05-27 Smith Kline Beecham Corporation Compounds
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ阻害剤としてのピラゾール
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1539748A1 (en) 2002-07-31 2005-06-15 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
CA2496295C (en) 2002-09-18 2010-11-23 Michael John Munchhof Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
EP1542995A1 (en) 2002-09-18 2005-06-22 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
AU2003256003A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
MXPA05002376A (es) 2005-05-23
UY27985A1 (es) 2004-04-30
EP2165708A3 (en) 2010-07-28
EP1542684A2 (en) 2005-06-22
JP2006507353A (ja) 2006-03-02
AR041272A1 (es) 2005-05-11
WO2004026306A3 (en) 2004-07-01
KR20050044807A (ko) 2005-05-12
AU2003259475A1 (en) 2004-04-08
JP4519657B2 (ja) 2010-08-04
PA8583201A1 (es) 2004-04-23
EP1542684B1 (en) 2009-12-02
US20040116474A1 (en) 2004-06-17
CA2496295C (en) 2010-11-23
MA27440A1 (fr) 2005-07-01
US20060025451A1 (en) 2006-02-02
EP2165708A2 (en) 2010-03-24
ES2335099T3 (es) 2010-03-22
US7151110B2 (en) 2006-12-19
CN1681501A (zh) 2005-10-12
IS7698A (is) 2005-02-17
AP2005003263A0 (en) 2005-03-31
DE60330362D1 (de) 2010-01-14
CO5550456A2 (es) 2005-08-31
OA12929A (en) 2006-10-13
NO20050838L (no) 2005-05-18
CA2496295A1 (en) 2004-04-01
PL375979A1 (en) 2005-12-12
PE20040988A1 (es) 2004-12-25
EA200500377A1 (ru) 2005-08-25
ATE450258T1 (de) 2009-12-15
BR0314302A (pt) 2005-07-05
US20100056571A1 (en) 2010-03-04
HRP20050247A2 (en) 2005-10-31
US7638537B2 (en) 2009-12-29
WO2004026306A2 (en) 2004-04-01
US20070117850A1 (en) 2007-05-24
US6958354B2 (en) 2005-10-25

Similar Documents

Publication Publication Date Title
ECSP055679A (es) Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)
UY27982A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
UY28214A1 (es) Nuevos compuestos heteroaromáticos condensados que son inhibidores del factor de crecimiento transformante (tgf)
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
UY27983A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
UY27891A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
AR048912A1 (es) Inmunoglobulinas anti-nogo
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
UY28679A1 (es) Nuevos derivados organofosforados de los indazoles y utilización como médicamentos.
UY28572A1 (es) Compuestos novedosos
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
CR7748A (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000718A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
CR7749A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000713A (es) Nuevos compuestos de pirarol como inhibidores delfactor de crecimiento transformante (tgf)
DOP2003000712A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
DOP2003000701A (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
DOP2003000719A (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
CR7747A (es) Nuevos compuestos derivados de isoxazol como inhibidores del factor de crecimiento transformador (tgf)